Q4 2024 Management View CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% ...

SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing results from the ENVISION trial assessing primary chemoablation ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Both TB treatment and TB preventive therapy involve taking lots of pills, usually for several months. Researchers are working ...

Transparent, well-designed clinical trials are a must. FastWave Medical's Scott Nelson has advice on how to get there.

Topline data were announced from a phase 3 trial evaluating solriamfetol in adults with attention deficit hyperactivity disorder (ADHD).

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Neurosense reports Canadian regulators want a meeting that could lead to PrimeC's conditional approval there, and further ...